 So House Subcommittee on Oversight and Investigations, Energy and Commerce Subcommittee. Mr. Tiger, did you need Mr. Tonko, before I turn the clock back on, did you need him to repeat his question? I don't. I think I got it. So the similarities or the contrasts in WADA's handling of Alieva, very similar if not identical facts, low level of a potent drug that's competitive.